Tenaya Therapeutics Inc (TNYA) Actualités

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

Funding will Support Ongoing RIDGE™-1 Clinical Trial of TN-401 Gene Therapy for the Potential Treatment of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing...

Form 8-K - Current report

Form 8-K - Current report

Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart...

Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a...

Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy

TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing...

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a...

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report